Breakout Stocks of Week 3
NASDAQ was up last week (week 2) by 3.09% ending at 14,972.76 points after gaining 448.69 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Alpine Immune Sciences Inc NASDAQ:ALPN. This stock has had a buy signal since Nov 03, 2023 when the price was $16.07 and is so far up 27.26% to $20.45. Some other companies are on our watchlist to, among these are Simon Property Group Inc NYSE:SPG Enel SpA MIL:ENEL Vitec Software Group AB (publ) OMX:VIT-B and Cerevel Therapeutics Holdings, Inc. NASDAQ:CERE which all got a breakout pattern emerging.
| Date | Company | Price | Week 3 |
|---|---|---|---|
| Alpine Immune Sciences Inc | $20.45 | $19.84 | -2.98% |
| Simon Property Group Inc | $146.62 | $141.62 | -3.41% |
| Enel Spa | 6.79€ | 6.66€ | -1.89% |
| Vitec Software Group Ab (publ) | kr590.00 | kr572.00 | -3.05% |
| Cerevel Therapeutics Holdings, Inc. | $42.70 | $42.25 | -1.05% |
The Alpine Immune Sciences Inc stock price gained 4.02% on the last trading day (Friday, 12th Jan 2024), rising from $19.66 to $20.45. During the last trading day the stock fluctuated 4.13% from a day low at $19.75 to a day high of $20.57. The price has fallen in 6 of the last 10 days but is still up by 4.55% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 62 thousand more shares were traded than the day before. In total, 861 thousand shares were bought and sold for approximately $17.61 million.
On Apr 15, 2024, it was reported that Cowen & Co. gave ALPN a "Hold" grade with a "downgrade" action.
Alpine Immune Sciences Inc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Alpine Immune Sciences Inc:
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
The Simon Property Group Inc stock price gained 1.55% on the last trading day (Friday, 12th Jan 2024), rising from $144.38 to $146.62. During the last trading day the stock fluctuated 1.52% from a day low at $144.44 to a day high of $146.63. The price has risen in 6 of the last 10 days and is up by 1.62% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 70 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately $238.01 million.
On Mar 25, 2024, it was reported that Stephens gave SPG a "Hold" grade with a "hold" action.
Simon Property Group Inc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Simon Property Group Inc:
Simon is a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations and an S&P 100 company (Simon Property Group, NYSE: SPG). Our properties across North America, Europe and Asia provide community gathering places for millions of people every day and generate billions in annual sales.
The Enel SpA stock price gained 1.77% on the last trading day (Friday, 12th Jan 2024), rising from 6.67€ to 6.79€. During the last trading day the stock fluctuated 1.34% from a day low at 6.70€ to a day high of 6.79€. The price has been going up and down for this period, and there has been a 1.21% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 2 million more shares were traded than the day before. In total, 24 million shares were bought and sold for approximately 161.61€ million.
Enel SpA holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Enel SpA:
Enel SpA operates as an integrated electricity and gas operator worldwide. The company generates, transmits, distributes, purchases, transports, and sells electricity; transports and markets natural gas; supplies LNG; designs, develops, constructs, operates, manages, and maintains generation plants and distribution grids; and designs, constructs, and operates merchant lines. It is also involved in various activities, such as energy and infrastructure engineering; research and development in sciences and engineering; the cogeneration of electricity and heat; the construction and management of manages port infrastructure; product, plant, and equipment certification; mining; finance; energy products marketing; trading; and fuel trading and logistics operations. In addition, the company engages in construction and management of LNG regasification infrastructure; desalinization and water supply; electricity system monitoring; and optical fiber network operation activities. Further, it provides testing, inspection, and certification; engineering and consulting; legal; metering, remote control, and connectivity through power line communication; business consulting, administrative, management consulting, and corporate planning; civil, mechanical, and electrical engineering; personnel administration, information technology, real estate, and business; electronic plant installation, maintenance, and repairing; and security services. Additionally, the company offers water systems; public lighting systems and services; electric mobility; and environmental studies services. It operates renewable, wind, thermal, hydroelectric, nuclear, photovoltaic, and geothermal power plants. The company was founded in 1962 and is headquartered in Rome, Italy.
The Vitec Software Group AB (publ) stock price gained 3.33% on the last trading day (Friday, 12th Jan 2024), rising from kr571.00 to kr590.00. During the last trading day the stock fluctuated 3.58% from a day low at kr572.50 to a day high of kr593.00. The price has risen in 6 of the last 10 days and is up by 0.77% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 35 thousand more shares were traded than the day before. In total, 55 thousand shares were bought and sold for approximately kr32.28 million.
Vitec Software Group AB (publ) holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Vitec Software Group AB (publ):
Addtech AB (publ.) operates as a technology trading company in Sweden, Denmark, Finland, Norway, rest of Europe, and internationally. The company operates through Automation, Electrification, Energy, Industrial Solutions, and Process Technology segments. It markets and sells intelligent solutions, subsystems, and components to industrial automation and infrastructure sector, including solutions for robotics, control systems, sensors, and industrial and communication networks. The company also offers battery systems; connectivity solutions; and intelligent power products, electronics, motors, and powertrain solutions. In addition, it produces and sells products for electricity transmission and electrical installation, as well as safety products for traffic and the home environment; and electricity distribution and communication network products to electricity network operators, contractors, wholesalers, railway companies, industrial customers, and hospitals. Further, the company produces and sells solutions and systems primarily for the forest, special vehicles, mechanical, and waste/recycling industries, as well as provides hydraulic solutions. Additionally, it provides process components, equipment, and systems for creating and processing flows; provides emission control products; and markets and sells instruments and valves for regulating and monitoring pressure, levels, flows, and energy. The company was founded in 1906 and is based in Stockholm, Sweden.
The Cerevel Therapeutics Holdings, Inc. stock price gained 0.141% on the last trading day (Friday, 12th Jan 2024), rising from $42.64 to $42.70. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 0.82% from a day low at $42.44 to a day high of $42.79. The price has been going up and down for this period, and there has been a 0.61% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 1 million more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately $117.90 million.
On Dec 07, 2023, it was reported that Piper Sandler gave CERE a "Neutral" grade with a "downgrade" action.
Cerevel Therapeutics Holdings, Inc. holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Cerevel Therapeutics Holdings, Inc.:
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
